AR075824A1 - 2- mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 - Google Patents
2- mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3Info
- Publication number
- AR075824A1 AR075824A1 ARP100100777A ARP100100777A AR075824A1 AR 075824 A1 AR075824 A1 AR 075824A1 AR P100100777 A ARP100100777 A AR P100100777A AR P100100777 A ARP100100777 A AR P100100777A AR 075824 A1 AR075824 A1 AR 075824A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- 2nhr0
- unsubstituted
- heteroaryl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Procedimiento para producirlas, medicamentos que contienen estos compuestos, así como uso de estos compuestos para la elaboracion de medicamentos. Reivindicacion 1: 2-mercaptoquinolin-3-carboxamidas sustituidas de la formula general (1), donde R0 representa al alquilo C1-10 o heteroalquilo C2-10, saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma simple o multiple; cicloalquilo C3-10 o heterociclilo, saturado o no saturado, no sustituido o sustituido en forma simple o multiple; arilo o heteroarilo, no sustituido o sustituido en forma simple o multiple; cicloalquilo C3-10 o heterociclilo con enlace por puente sobre alquilo C1-8 o heteroalquilo C2-8, saturado o no saturado, no sustituido o sustituido en forma simple o multiple, en el cual la cadena de alquilo o heteroalquilo puede estar ramificada o no ramificada, saturada o no saturada, no sustituida, sustituida en forma simple o multiple; o arilo o heteroarilo con enlace por puente sobre alquilo C1-8 o heteroalquilo C2-8, no sustituido o sustituido en forma simple o multiple, en el cual la cadena de alquilo o heteroalquilo puede estar ramificada o no ramificada, saturada o no saturada, no sustituida, sustituida en forma simple o multiple; R1, R2, R3, R4 significan, independientemente entre sí, H; F; CI; Br; I; NO2; CF3; CN; R0; C(=O)H; C(=O)R0; CO2H; C(=O)OR0; CONH2; C(=O)NHR0; C(=O)N(R0)2; OH; OR0; O-C(=O)-R0; O-C(=O)-O-R0; O-(C=O)-NH-R0; O-C(=O)-N(R0)2; O-S(=O)2-R0; O-S(=O)2OH; O-S(=O)2OR0; O-S(=O)2NH2; O-S(=O)2NHR0; O-S(=O)2N(R0)2; NH2; NH-R0; N(R0)2; NH-C(=O)-R0; NH-C(=O)O-R0; NH-C(=O)-NH2; NH-C(=O)-NH-R0; NH-C(=O)-N(R0)2; NR0-C(=O)-R0; NR0-C(=O)-O-R0; NR0-C(=O)-NH2; NR0-C(=O)-NH-R0; NR0-C(=O)-N(R0)2; NH-S(=O)2OH; NH-S(=O)2R0; NH-S(=O)2OR0; NH-S(=O)2NH2; NH-S(=O)2NHR0; NH-S(=O)2N(R0)2; NR0-S(=O)2OH; NR0-S(=O)2R0; NR0-S(=O)2OR0; NR0-S(=O)2NH2; NR0-S(=O)2NHR0; NR0-S(=O)2N(R0)2; SH; SR0; S(=O)R0; S(=O)2R0; S(=O)2OH; S(=O)2OR0; S(=O)2NH2; S(=O)2NHR0; o bien S(=O)2N(R0)2; R5 representa H; F; CI; Br; I; NO2; CF3; CN; R0; C(=O)H; C(=O)R0; CO2H; C(=O)OR0; CONH2; C(=O)NHR0; C(=O)N(R0)2; OR0; O-C(=O)-R0; O-C(=O)-O-R0; O-(C=O)-NH-R0; O-C(=O)-N(R0)2; O-S(=O)2-R0; O-S(=O)2OH; O-S(=O)2OR0; O-S(=O)2NH2; O-S(=O)2NHR0; O-S(=O)2N(R0)2; NH2; NH-R0; N(R0)2; NH-C(=O)-R0; NH-C(=O)O-R0; NH-C(=O)-NH2; NH-C(=O)-NH-R0; NH-C(=O)-N(R0)2; NR0-C(=O)-R0; NR0-C(=O)-O-R0; NR0-C(=O)-NH2; NR0-C(=O)-NH-R0; NR0-C(=O)-N(R0)2; NH-S(=O)2OH; NH-S(=O)2R0; NH-S(=O)2OR0; NH-S(=O)2NH2; NH-S(=O)2NHR0; NH-S(=O)2N(R0)2; NR0-S(=O)2OH; NR0-S(=O)2R0; NR0-S(=O)2OR0; NR0-S(=O)2NH2; NR0-S(=O)2NHR0; NR0-S(=O)2N(R0)2; SH; SR0; S(=O)R0; S(=O)2R0; S(=O)2OH; S(=O)2OR0; S(=O)2NH2; S(=O)2NHR0; o bien S(=O)2N(R0)2; R6 representa R0; con la reserva de que cuando R0 signifique heterociclilo, saturado o no saturado, no sustituido o sustituido en forma simple o multiple; o heteroarilo, no sustituido o sustituido en forma simple o multiple, el enlace del heteroarilo o heterociclilo se realice sobre un átomo de carbono del heteroarilo o heterociclilo; R7 representa R0; con la reserva de que cuando R0 signifique heterociclilo, saturado o no saturado, no sustituido o sustituido en forma simple o multiple; o heteroarilo, no sustituido o sustituido en forma simple o multiple, el enlace del heteroarilo o heterociclilo se realice sobre un átomo de carbono del heteroarilo o heterociclilo; donde ôalquilo sustituidoö, ôheteroalquilo sustituidoö, ôheterociclilo sustituidoö y ôcicloalquilo sustituidoö representa la sustitucion de uno o más átomos de hidrogeno, independientes entre sí, por medio de F; CI; Br; I; CN; CF3; =O; =NH; =C(NH2)2; NO2; R0; C(=O)H; C(=O)R0; CO2H; C(=O)OR0; CONH2; C(=O)NHR0; C(=O)N(R0)2; OH; OR0; -O-alquilo C1-8-O; O-C(=O)-R0; O-C(=O)-O-R0; O-(C=O)-NH-R0; O-C(=O)-N(R0)2; O-S(=O)2-R0; O-S(=O)2OH; O-S(=O)2OR0; O-S(=O)2NH2; O-S(=O)2NHR0; O-S(=O)2N(R0)2; NH2; NH-R0; N(R0)2; NH-C(=O)-R0; NH-C(=O)O-R0; NH-C(=O)-NH2; NH-C(=O)-NH-R0; NH-C(=O)-N(R0)2; NR0-C(=O)-R0; NR0-C(=O)-O-R0; NR0-C(=O)-NH2; NR0-C(=O)-NH-R0; NR0-C(=O)-N(R0)2; NH-S(=O)2OH; NH-S(=O)2R0; NH-S(=O)2OR0; NH-S(=O)2NH2; NH-S(=O)2NHR0; NH-S(=O)2N(R0)2; NR0-S(=O)2OH; NR0-S(=O)2R0; NR0-S(=O)2OR0; NR0-S(=O)2NH2; NR0-S(=O)2NHR0; NR0-S(=O)2N(R0)2; SH; SR0; S(=O)R0; S(=O)2R0; S(=O)2H; S(=O)2OH; S(=O)2OR0; S(=O)2NH2; S(=O)2NHR0; S(=O)2N(R0)2; donde ôarilo sustituidoö y ôheteroarilo sustituidoö representa la sustitucion de uno o más átomos de hidrogeno, independientes entre sí, por medio de F; CI; Br; I; NO2; CF3; CN; R0; C(=O)H; C(=O)R0; CO2H; C(=O)OR0; CONH2; C(=O)NHR0; C(=O)N(R0)2; OH; OR0; -O-alquilo C1-8-O; O-C(=O)-R0; O-C(=O)-O-R0; O-(C=O)-NH-R0; O-C(=O)-N(R0)2; O-S(=O)2-R0; O-S(=O)2OH; O-S(=O)2OR0; O-S(=O)2NH2; O-S(=O)2NHR0; O-S(=O)2N(R0)2; NH2; NH-R0; N(R0)2; NH-C(=O)-R0; NH-C(=O)O-R0; NH-C(=O)-NH2; NH-C(=O)-NH-R0; NH-C(=O)-N(R0)2; NR0-C(=O)-R0; NR0-C(=O)-O-R0; NR0-C(=O)-NH2; NR0-C(=O)-NH-R0; NR0-C(=O)-N(R0)2; NH-S(=O)2OH; NH-S(=O)2R0; NH-S(=O)2OR0; NH-S(=O)2NH2; NH-S(=O)2NHR0; NH-S(=O)2N(R0)2; NR0-S(=O)2OH; NR0-S(=O)2R0; NR0-S(=O)2OR0; NR0-S(=O)2NH2; NR0-S(=O)2NHR0; NR0-S(=O)2N(R0)2; SH; SR0; S(=O)R0; S(=O)2R0; S(=O)2OH; S(=O)2OR0; S(=O)2NH2; S(=O)2NHR0; S(=O)2N(R0)2; a excepcion del siguiente compuesto: N-bencil-2-(3-cloro-2-hidroxipropiltio)-4-(2,4-diclorofenil)quinolin-3-carboxamida; en forma de compuestos o sales libres fisiologicamente compatibles con ácidos o bases.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09003597 | 2009-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR075824A1 true AR075824A1 (es) | 2011-04-27 |
Family
ID=40671387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100777A AR075824A1 (es) | 2009-03-12 | 2010-03-12 | 2- mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 |
Country Status (20)
Country | Link |
---|---|
US (2) | US20100234372A1 (es) |
EP (1) | EP2406229A1 (es) |
JP (1) | JP5727946B2 (es) |
KR (1) | KR20110132590A (es) |
CN (1) | CN102348692A (es) |
AR (1) | AR075824A1 (es) |
AU (1) | AU2010223513B2 (es) |
BR (1) | BRPI1008939A2 (es) |
CA (1) | CA2755004A1 (es) |
CL (1) | CL2011002209A1 (es) |
CO (1) | CO6410292A2 (es) |
EC (1) | ECSP11011348A (es) |
IL (1) | IL214945A0 (es) |
MX (1) | MX2011009369A (es) |
NZ (1) | NZ595625A (es) |
PE (1) | PE20120790A1 (es) |
RU (1) | RU2011141188A (es) |
TW (1) | TWI461197B (es) |
WO (1) | WO2010102811A1 (es) |
ZA (1) | ZA201107444B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
WO2010102778A2 (de) * | 2009-03-10 | 2010-09-16 | Grünenthal GmbH | Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren |
TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
US8653102B2 (en) | 2010-08-27 | 2014-02-18 | Gruenenthal Gmbh | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators |
AU2011295405B2 (en) | 2010-08-27 | 2015-01-22 | Grünenthal GmbH | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
US8618129B2 (en) | 2010-09-01 | 2013-12-31 | Gruenenthal Gmbh | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators |
WO2014056620A1 (en) | 2012-10-11 | 2014-04-17 | Grünenthal GmbH | Treatment and/or prophylaxis of tspo mediated diseases and/or disorders |
AU2013351550A1 (en) * | 2012-11-28 | 2015-07-16 | Grünenthal GmbH | Specific carboxamides as KCNQ2/3 modulators |
WO2014082738A1 (en) | 2012-11-28 | 2014-06-05 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |
US9248122B2 (en) | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
KR102226587B1 (ko) * | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
WO2014121062A1 (en) | 2013-02-01 | 2014-08-07 | Acetylon Pharmaceuticals, Inc. | Selective hdac3 inhibitors |
US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
PH12015000236A1 (en) * | 2015-07-06 | 2017-01-23 | Samsung Electronics Co Ltd | Electronic device for providing a calibrated keyboard configuration |
CN109688818A (zh) | 2016-09-08 | 2019-04-26 | 卡拉制药公司 | 治疗化合物的晶型及其用途 |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018110669A1 (en) | 2016-12-15 | 2018-06-21 | Ono Pharmaceutical Co., Ltd. | Activator of trek (twik related k+ channels) channels |
DE102018212006B3 (de) | 2018-07-18 | 2019-10-31 | Universität Greifswald | Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
WO1996026925A1 (fr) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Derives de l'arylthioacetamide |
DE19738615A1 (de) * | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
DE19738616A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
JP2002534512A (ja) * | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
JP2003506388A (ja) | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | 疼痛および不安症を処置または予防するための方法 |
DE60037321D1 (de) | 1999-08-04 | 2008-01-17 | Icagen Inc | Benzanilide als öffner des kaliumkanals |
WO2002066036A1 (en) | 2001-02-20 | 2002-08-29 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
US6855829B2 (en) * | 2001-02-20 | 2005-02-15 | Bristol-Myers Squibb Company | 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease |
US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
EP1372654A4 (en) * | 2001-04-06 | 2007-10-03 | Smithkline Beecham Corp | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES |
JP2005539081A (ja) | 2002-09-17 | 2005-12-22 | ファルマシア コーポレイション | 芳香族肝臓x受容体モジュレーター |
CA2505195C (en) | 2002-12-23 | 2012-07-10 | Icagen, Inc. | Quinazolinones as potassium channel modulators |
EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
RU2006115602A (ru) | 2003-10-08 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы переносчиков атф-связывающих кассет |
BRPI0510598A (pt) | 2004-05-04 | 2007-11-20 | Pfizer | compostos de amida de aril ou heteroaril substituìdos |
CA2810655C (en) * | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
JP2008519814A (ja) | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
EP2298766B1 (en) | 2005-03-03 | 2013-09-18 | H. Lundbeck A/S | Pharmaceutical formulations comrpising a substituted pyridine derivative |
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
ATE432259T1 (de) | 2005-07-20 | 2009-06-15 | Lilly Co Eli | Pyridinderivate als dipeptedyl-peptidase-hemmer |
EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
EP1951685A1 (en) | 2005-11-18 | 2008-08-06 | NeuroSearch A/S | Novel quinazoline derivatives and their medical use |
US7872128B2 (en) | 2006-07-20 | 2011-01-18 | Amgen Inc. | Benzisoxazole and isoxazolo-pyridine compounds and method of use |
CA2658190C (en) | 2006-07-20 | 2013-01-29 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
MX2009005652A (es) * | 2006-11-28 | 2009-08-07 | Valeant Pharmaceuticals Int | Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio. |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
KR101167773B1 (ko) | 2007-08-03 | 2012-07-24 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 피리딘카복스아마이드 및 벤즈아마이드 유도체 |
US8299123B2 (en) | 2007-10-19 | 2012-10-30 | Boehringer Ingelheim International Gmbh | CCR10 antagonists |
TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
WO2010102778A2 (de) * | 2009-03-10 | 2010-09-16 | Grünenthal GmbH | Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren |
TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
TW201038565A (en) * | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
-
2010
- 2010-02-24 TW TW099105238A patent/TWI461197B/zh not_active IP Right Cessation
- 2010-03-10 US US12/720,864 patent/US20100234372A1/en not_active Abandoned
- 2010-03-11 AU AU2010223513A patent/AU2010223513B2/en not_active Ceased
- 2010-03-11 KR KR1020117023788A patent/KR20110132590A/ko not_active Application Discontinuation
- 2010-03-11 PE PE2011001567A patent/PE20120790A1/es not_active Application Discontinuation
- 2010-03-11 CN CN2010800112967A patent/CN102348692A/zh active Pending
- 2010-03-11 WO PCT/EP2010/001509 patent/WO2010102811A1/de active Application Filing
- 2010-03-11 CA CA2755004A patent/CA2755004A1/en not_active Abandoned
- 2010-03-11 MX MX2011009369A patent/MX2011009369A/es active IP Right Grant
- 2010-03-11 NZ NZ595625A patent/NZ595625A/xx not_active IP Right Cessation
- 2010-03-11 BR BRPI1008939A patent/BRPI1008939A2/pt not_active IP Right Cessation
- 2010-03-11 JP JP2011553352A patent/JP5727946B2/ja not_active Expired - Fee Related
- 2010-03-11 RU RU2011141188/04A patent/RU2011141188A/ru not_active Application Discontinuation
- 2010-03-11 EP EP10708726A patent/EP2406229A1/de not_active Withdrawn
- 2010-03-12 AR ARP100100777A patent/AR075824A1/es not_active Application Discontinuation
-
2011
- 2011-08-24 CO CO11107978A patent/CO6410292A2/es not_active Application Discontinuation
- 2011-09-04 IL IL214945A patent/IL214945A0/en unknown
- 2011-09-08 CL CL2011002209A patent/CL2011002209A1/es unknown
- 2011-09-23 EC EC2011011348A patent/ECSP11011348A/es unknown
- 2011-10-11 ZA ZA2011/07444A patent/ZA201107444B/en unknown
-
2012
- 2012-06-15 US US13/523,955 patent/US8399673B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CL2011002209A1 (es) | 2012-02-10 |
PE20120790A1 (es) | 2012-07-08 |
ZA201107444B (en) | 2012-06-27 |
CN102348692A (zh) | 2012-02-08 |
MX2011009369A (es) | 2011-09-27 |
US8399673B2 (en) | 2013-03-19 |
US20100234372A1 (en) | 2010-09-16 |
BRPI1008939A2 (pt) | 2016-03-15 |
JP2012520249A (ja) | 2012-09-06 |
CO6410292A2 (es) | 2012-03-30 |
ECSP11011348A (es) | 2011-10-31 |
TWI461197B (zh) | 2014-11-21 |
EP2406229A1 (de) | 2012-01-18 |
JP5727946B2 (ja) | 2015-06-03 |
US20120252841A1 (en) | 2012-10-04 |
WO2010102811A1 (de) | 2010-09-16 |
KR20110132590A (ko) | 2011-12-08 |
AU2010223513A1 (en) | 2011-11-03 |
TW201034670A (en) | 2010-10-01 |
RU2011141188A (ru) | 2013-04-20 |
NZ595625A (en) | 2012-10-26 |
AU2010223513B2 (en) | 2014-12-04 |
IL214945A0 (en) | 2011-11-30 |
CA2755004A1 (en) | 2010-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR075824A1 (es) | 2- mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 | |
AR076753A1 (es) | Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides. | |
AR075730A1 (es) | 3-amino-2-mercaptoquinolina sustituida como moduladores de kcnq2/3 | |
AR083817A1 (es) | Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide | |
ES2539430T3 (es) | Derivados de metastina y uso de los mismos | |
ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
SV2009003157A (es) | Profarmaco de compuesto de cinamida | |
SE0502254L (sv) | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission | |
AR082498A1 (es) | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide | |
ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten | |
RU2009106448A (ru) | Стенд | |
EA201100503A1 (ru) | Глюкозидные производные и их применения | |
EA200901563A1 (ru) | Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой | |
TR201902609T4 (tr) | İbandronat polimorf A nın tıbbi kullanımı. | |
EA201071019A1 (ru) | Кристаллические формы производных фениламинопиримидина | |
EA201270216A1 (ru) | Фармацевтический состав | |
RS54485B1 (en) | C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS | |
AR070578A1 (es) | Imidazolidinas fenil- sustituidas, medicamentos que comprenden dichos compuestos y su uso para producir medicamentos | |
EA201001766A1 (ru) | Новые[f-18]-меченые производные l-глутаминовой кислоты и l-глутамина (i), их применение, а также способ их получения | |
DOP2011000329A (es) | Preparacion de solido | |
EA200700997A1 (ru) | 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ | |
AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
EA200900707A1 (ru) | Новый способ синтеза 7,8-диметокси-1,3-дигидро-2h-3-бензазепин-2-она, и его применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой | |
ECSP109961A (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica | |
AR082734A1 (es) | Quinolino-3-carboxamidas sustituidas como moduladores de kcnq2/3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |